KEGG   DRUG: IpilimumabHelp
Entry
D04603                      Drug                                   

Name
Ipilimumab (USAN/INN);
Ipilimumab (genetical recombination) (JAN);
Yervoy (TN)
Product
Formula
C6472H9972N1732O2004S40
Exact mass
145300.0471
Mol weight
145389.4301
Sequence
(Heavy chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVTF ISYDGNNKYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAIYYCARTG WLGPFDYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQSVG SSYLAWYQQK PGQAPRLLIY GAFSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(dimer; disulfide brigde: H22-H96, H145-H201, H221-L215, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'215, H'262-H'322, H'368-H'426, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01XC11
Product: D04603<JP/US>
Efficacy
Antineoplastic, Immune checkpoint inhibitor, Anti-CTLA-4 antibody
  Disease
Melanoma [DS:H00038]
Comment
Monoclonal antibody
Target
CTLA4 (CD152) [HSA:1493] [KO:K06538]
  Pathway
hsa04660  T cell receptor signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC11 Ipilimumab
      D04603  Ipilimumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D04603  Ipilimumab (USAN/INN); Ipilimumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D04603  Ipilimumab (USAN/INN) <JP/US>
Antineoplastics [br08340.html]
 D04603
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D04603
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D04603
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D04603
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D04603
BRITE hierarchy
Other DBs
CAS: 477202-00-9
PubChem: 47206447
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system